Daewoong Pharmaceutical is a South Korean pharmaceutical company focused on developing and supplying medicines. Its official R&D overview identifies new drugs, biopharmaceuticals and platform technologies as core research areas. The company lists pipeline programs in metabolic disease, autoimmunity, fibrosis and oncology.[3][4]
The company’s timeline highlights the 2022 launch of Fexuclue, a P-CAB treatment for gastroesophageal reflux disease, and the 2023 launch of Enblo, an SGLT-2 inhibitor for diabetes. Daewoong reports operating eight overseas subsidiaries and branches across its research, development, manufacturing and sales network.[3][5]
Daewoong Pharmaceutical lists its head office at 12 Bongeunsa-ro 114-gil in Seoul’s Gangnam District. T1 currently lists Daewoong Pharmaceutical in its supporter tier.[2][1]
